Eco Animal Health Group PLC Trading Update on year ended 31 March 2024

RNS Number : 9132L

Eco Animal Health Group PLC

25 April 2024

 

25 April 2024

 

  

ECO Animal Health Group plc

("ECO" or the "Company")

 

Trading Update

Company to report stronger than anticipated revenue performance

EBITDA in-line with market expectations

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today announces a preliminary update on its profits for the year ending 31 March 2024.

As announced on 21 March 2024, the Board expected revenues for the year ending 31 March 2024 to be in line with market expectations. Market expectations for FY24 Revenue as at the date of this announcement are £88.7m. With full visibility on trading for the year, the Company can report that final revenues were greater than market expectations and nearly £90m.

Overperformance in revenue generation was achieved despite foreign exchange headwinds experienced in the early part of the financial year. When presented on a constant currency basis the Board expects to report revenue growth in excess of 10% over the year ended 31 March 2023.

Subject to audit, EBITDA for the year ended 31 March 2024 will be in line with market expectations (current market expectations are £7.8m). This robust EBITDA result was delivered against a backdrop of heavy investment in new product innovation, which the Board believes will be a key driver of future growth, and against challenging market conditions in some regions.

Total cash on 31 March 2024 was approximately £22m.

David Hallas, Chief Executive Officer of ECO Animal Health Group plc, commented: "I am delighted to be able to confirm that ECO has delivered strongly on its profit expectations. We are particularly pleased to have achieved these positive results despite experiencing challenging market conditions, currency headwinds, and while continuing to invest heavily in our promising R&D pipeline, which we believe has significant potential to drive future growth and value for shareholders. We look forward to completing the audit and releasing our Annual Report and Accounts in July."

-Ends-

For further information please contact:

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) 020 8447 8899   Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher 020 7496 3000 Investec (Joint Broker) Gary Clarence Lydia Zychowska 020 7597 5970     Equity Development Hannah Crowe Matt Evans 020 7065 2692 ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson 020 3709 5700 [e-mail]

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

TSTQKQBDPBKDQQB